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Heparin, the drug of choice for the prevention and
treatment of thromboembolic disorders, has been
shown to interact with many proteins. Despite its
widespread medical use, little is known about the pre-
cise sequences that interact with specific proteins.
The minimum heparin binding sequence for FGF1 and
FGF2 necessary to promote signaling was investi-
gated. A characteristic pentasaccharide sequence,
DEFGH, is required to accelerate the inhibition of
thrombin and factor Xa in the blood-coagulation cas-
cade. The first synthetic heparin pentasaccharide
drug has been approved in Europe and the US and is
sold under the trade name Arixtra. Other oligosaccha-
rides with different composition are under clinical in-
vestigation. The enormous interest in the assembly
of heparin oligosaccharides will stimulate the devel-
opment of new synthetic approaches. Heparin-oligo-
saccharide-synthesis automation similar to that of
DNA or peptide synthesis will play an important role.
Introduction
Proteoglycans are major components of the extracellu-
lar matrix that surround all mammalian cells. Different
core proteins anchor glycosaminoglycan polysaccha-
rides in the outside of the lipid bilayer. Heparin and hep-
aran sulfate are the most complex glycosaminoglycans
(GAGs), a family of molecules that also includes chon-
droitin sulfate, keratin sulfate, and dermatan sulfate.
GAGs have important biological functions by binding
to different growth factors, enzymes, morphogens, cell
adhesion molecules, and cytokines [1–5].
Heparin, found only in mastocytes, has served as an
anticoagulant in heart disease for more than 60 years
[6, 7]. It has a molecular weight ranging from 5 to 40
kDa, with an average molecular weight of about 15 kDa.
These linear, unbranched, highly sulfated polysaccha-
rides are composed of disaccharide units consisting of
a uronic acid 1,4-linked to a D-glucosamine unit (Figure
1). The uronic acid residues are more often L-iduronic
acid (90%) than its C5 epimer D-glucuronic acid (10%).
A prototypical heparin disaccharide contains three sul-
fate groups. These sulfate groups render heparin one of
the most acidic macromolecules in nature. O-sulfation
normally occurs at the 2 position of the uronic acids
and the 3- and/or 6-position of the glucosamine. In ad-
dition, the glucosamine nitrogen may be sulfated, acet-
ylated or, less frequently, may remain unmodified, thus*Correspondence: seeberger@org.chem.ethz.chresulting in 48 possible disaccharides that make up
heparin [8].
Heparan sulfate is structurally related to heparin but
is widely distributed in different cell types and tissues.
With a molecular weight range of 5 to 50 kDa and an
average molecular weight of 30 kDa, heparan sulfate
chains are generally longer than those of heparin. Hep-
aran sulfate is more heterogeneous than heparin, is
richer in N-acetyl D-glucosamine (GlcNAc) and D-glucu-
ronic acid (GlcA) units, and contains less O-sulfates [9].
Much research on the structure, function, and biolog-
ical activity of heparin and heparan sulfate has been
carried out. A more detailed structure-activity relation-
ship for heparin oligosaccharides has evolved in recent
years. This more-detailed understanding of GAGs has
been aided by the availability of synthetic, completely
defined heparin oligosaccharides. Because many as-
pects of heparin chemistry [10–13] and biology [4, 14,
15] have been reviewed recently, after a brief general
introduction, we will focus on studies using synthetic
heparin oligosaccharides to elucidate the SAR of hepa-
rin and heparan sulfate.
Biosynthesis
To understand the way GAG sequences interact with
particular proteins, it is helpful to consider the mecha-
nism by which nature synthesizes different heparins.
Much progress in understanding GAG biosynthesis has
been made in recent years [16]. Heparin and heparan
sulfate are assembled via a similar pathway. Chain initi-
ation occurs in the Golgi apparatus. A tetrasaccharide
unit that is attached to a core protein primes chain
elongation. N-Acetyl D-glucosamine and glucuronic
acid monosaccharide units are alternatingly incorpo-
rated from the nonreducing end of the nascent polymer
with the corresponding sugar nucleotides. Glucuronic
acid is attached by glucuronyltransferase followed by
the addition of the first N-acetyl glucosamine residue.
Two glycosyl transferases (EXT1 and EXT2) that form a
hetero-oligomeric complex in the Golgi are responsible
for the disaccharide addition [17]. As the polysaccha-
ride chain forms, it undergoes a series of modification
reactions catalyzed by at least four families of sulfo-
transferases and one epimerase [18]: N-deacetylation
and N-sulfation is carried out by a N-deacetylase and a
N-sulfotransferase. The transformation of D-glucuronic
units to L-iduronic units is catalyzed by a C-5 epi-
merase. Different O-sulfotransferases are responsible
for O-sulfation of the iduronic acid residues. The action
of these enzymes results in tremendous heterogeneity
within modified regions.
Structure of Heparin/Heparan Sulfate
Heparin does not fold into tertiary structures like pro-
teins but exists primarily as a helical structure [19]. The
sulfate and carboxyl groups of heparin promote spe-
cific interactions with biologically important proteins
[20]. The pyranose rings of the monosaccharide resi-
dues within heparin oligosaccharides adopt the 1C4
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732Figure 1. Major and Minor Disaccharide Re-
peating Units in Heparin and Heparan
Sulfate
X = H or SO3−; Y = Ac, SO3−, or H.and 4C1 chair conformation as well as the 2S0 skew- f
tboat conformation [21–23]. NMR studies and X-ray
structures show that the pyranose rings of glucuronic f
pacid and glucosamine residues prefer the 4C1 chair
conformation whereby all nonhydrogen substituents, F
texcept the anomeric hydroxyl group of glucosamine,
are equatorial [24, 25]. The iduronic acid pyranose is a
gmore flexible: bearing a sulfate group at C-2, the 1C4
chair and the 2S0 skew-boat conformation are pre- t
Wferred. Unsubstituted iduronic acid, however, resides
predominantly in the 1C4 form [24, 26]. The flexibility of t
gthe L-iduronic acid residues is important for specific
heparin-protein interactions. a
dDifferent attractive forces are responsible for the hep-
arin-protein interplay: ionic interactions are dominant f
las the negatively charged sulfate and carboxyl groups
form ion pairs with positively charged amino acids on w
Gthe protein [27]. Nonionic interactions such as hy-
drogen bonding as well as hydrophobic forces also
contribute to the binding. The binding affinity of the in-
teraction depends on the ability of the oligosaccharide H
Msequence to provide optimal charge (orientation of the
sulfates) and surface (van der Waals contact) compli- r
mentary with the protein. Crystal structure of highly sul-ated GAG oligosaccharides have shown that ionic con-
acts are not sufficient to explain the optimal structural
it of a GAG oligosaccharide to the binding site of the
rotein, which influences the affinity of the interaction.
rom the conformation of the GAG, it can be envisioned
hat protein binding would induce local distortions that
re manifested as changes in the glycosidic torsion an-
les. These conformation changes would enable an op-
imal structural fit in the terms of both ionic and van der
aals contacts between the oligosaccharide motif and
he protein [28]. The complexity of GAG polymers has
reatly complicated the evolution of detailed structure-
ctivity relationships. However, it has been shown that
efined length and sequences of GAGs are responsible
or the binding to proteins and hence modulate the bio-
ogical activity of particular proteins. A more detailed
ork on the structural insights into biological roles of
AGs and proteins has recently been reviewed [29].
eparin Sequences of Biological Significance
any aspects of heparin binding proteins have been
eviewed [4], and the best studied interactions are
briefly summarized below.
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Many growth factors, including the fibroblast growth
factors (FGFs), bind to the extracellular matrix of target
tissues by interacting with GAGs such as heparin and
heparan sulfate. The mammalian FGFs belong to a pro-
tein family involved in cell proliferation, differentiation,
and angiogenesis. Growth factors bind relatively tightly
to GAGs [30–32].
Heparin interacts directly with the FGF2 receptor and
mediates a high affinity FGF,FGFR complex [33]. One
FGF molecule binds to four to five saccharide units in
heparin (Figure 2A) [34, 35]. Heparan sulfate stabilizes
the formation of FGF oligomers, an essential step to
promote the oligomerization and activation of tyrosine
kinase FGF receptor (FGFR). The FGFs interact with
two distinct extracellular receptors and proteoglycan
modified FGFR dimerization activates the FGF-medi-
ated signal-transduction process.
The most thoroughly studied members of the fibro-
blast growth-factor family are FGF1 (acidic FGF) and
FGF2 (basic FGF). The minimum heparin sequences re-
quired for FGF1 and FGF2 to promote assembly of
active structures have been determined [36–40]. Short
oligomers such as tri- and pentasaccharides are able
to bind FGF2 [31, 37, 41]; however, longer oligomers
are necessary for dimerization and activation of FGFs
[42]. X-ray crystal structures of FGF1 [43] and FGF2 [31]
complexed with heparin oligosaccharides helped iden-
tify functional groups crucial for signaling [19]. The
binding region for FGF2 has been identified as a penta-
saccharide sequence containing a single, essential,
O-sulfate group at C2 of iduronic acid [41] and N-sul-
fated D-glucosamine. For efficient binding of FGF2, all
uronic acid units must be present as L-iduronic acidsFigure 2. Heparin Oligosaccharides
(A) The FGF binding domain.
(B) The AT III binding domain: a heparin molecule contains an antithrombin binding domain (ABD) and thrombin binding domains (TBD).[44, 45]. Although 6-O-sulfate groups are necessary forbinding and activation of FGF1, sulfates are not re-
quired for binding to FGF2 [41, 46] but are thought to be
essential for the mitogenic activity of FGF2 [47]. Crystal
structures of FGF-heparin complexes further strengthen
these observations [31, 43]. Although FGF-heparin in-
teractions are dominated by interactions involving sul-
fate groups, nonsulfated oligosaccharides can also
bind to the same site, as shown by the structure of a
complex between FGF2 and a trisaccharide heparin-
derivative [37]. For the FGF system, only one structure
has been determined with sufficient resolution to allow
for the direct identification of the structural details of
the glycan [31].
Interactions With Antithrombin III
The most thoroughly studied heparin binding protein is
the serine protease inhibitor antithrombin III (AT III) that
interacts with thrombin and factor Xa in the blood-
coagulation cascade [10]. The heparin-AT III interaction
is responsible for the anticoagulant activity of heparin.
A characteristic heparin pentasaccharide sequence,
termed DEFGH, is necessary for binding to AT III, a pro-
cess that has been studied in great detail [48, 49], in-
cluding NMR spectroscopy [50] and X-ray crystallogra-
phy [31, 51].
Crystallographic studies of an AT III/pentasaccharide
complex have identified the important functional groups
within the pentasaccharide sequence: four charged
sulfate groups and two carboxyl groups are responsible
for the binding to AT III [52]. The importance of the
3-O-sulfate group in unit F of the AT III binding site [53]
was demonstrated by NMR. The 6-O-sulfate substitu-
ent of glucosamine D [54, 55], the N-sulfate group of
unit F [56], and the carboxylate group of the iduronic
acid residue G are also required for binding to AT III and
affect anticoagulant activity. The 2-O-sulfate group on
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(A) Synthesis of the regular sequence disaccharides of heparin.
(B) Synthesis of the 1,6-anhydro-β-L-hexopyranose.iduronic acid G and the 6-O-sulfate group of unit H are h
tnot essential for binding but contribute to the overall
binding affinity [57]. i
nHeparin’s antithrombotic activity results from a ter-
nary complex formed by heparin, AT III, and thrombin t
a[58, 59]. The interaction of AT III with the pentasaccha-
ride sequence DEFGH results in a conformational m
mchange of the protein [4, 60]. AT III-pentasaccharide
binding directly accelerates the inhibition of factor Xa A
Abut not that of thrombin. The SAR of thrombin inhibition
is much more complicated. In the case of thrombin, a p
nconformational change is not sufficient to neutralize the
enzyme. Although the pentasaccharide sequence is re- i
pquired for binding to AT III, a heparin chain containing
14–20 saccharide units is required to accelerate the AT n
iIII/thrombin interaction (Figure 2B). Heparin forms a
bridge between AT III and thrombin in the ternary AT t
mIII/heparin/thrombin complex containing 6 to 8 sulfated
monosaccharide units that do not interact with protein.
iAlthough the thrombin inhibition is a desirable effect
of heparin, nonspecific interactions with other proteins X
w(e.g., platelet factor 4) result in life-threatening side ef-
fects [61–63]. 6
iChemokine Interactions
Chemokines, a family of over 40 structurally related gly- h
coproteins that facilitate leukocyte migration, angio-
genesis, breast cancer metastasis [64], and leukocyte C
Odegranulation, also interact with heparin. Platelet factor
4 (PF-4, CXC chemokine ligand 4), a basic tetramer of A
midentical subunits, forms a very stable 1:1 complex witheparin (MW > 10,000) [65]. Therapeutically adminis-
ered heparin binds to PF-4, thus resulting in heparin-
nduced thrombocytopenia (HIT), a dangerous, immu-
ologically induced loss of platelets. Other chemokines
hat bind to heparin with varying affinity and specificity
re the stromal-cell-derived factor-1α (SDF-1α), the
onocyte chemoattractant protein-1 (MCP-1), and the
acrophage inflammatory peptide-1 (MIP-1).
nnexin Interactions
nnexins comprise a family of over 30 calcium and
hospholipids binding proteins. At least one of the an-
exins is expressed in nearly every eukaryotic cell type
ndicating the wide range of biological functions. The
hospholipid/membrane binding properties of the an-
exins are responsible for their anti-inflammatory activ-
ty and exhibit anticoagulant and calcium-channel ac-
ivity [66, 67]. In addition, annexins are involved in
embrane fusion, exocytosis, and endocytosis [68].
Annexin V is one of the few proteins that bind heparin
n a calcium-dependent manner [69] as verified by
-ray crystallography [70]. The interaction of annexin V
ith heparin involves an oligosaccharide sequence of
–8 residues [69], and sulfate groups on heparin are
mportant. Annexins IV, V, and VI were found to bind to
eparin, heparan sulfate, and chondroitin sulfate [71].
hemical Synthesis of Defined Heparin
ligosaccharides
ccess to defined heparin oligosaccharides is of ut-
ost importance to establish a detailed SAR- and cor-
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735Figure 4. Buildings Blocks for the Assembly of Heparin Oligosaccharides
(A) Building blocks for the synthesis of 20 different heparan sulfate disaccharide units.
(B) Disaccharide moieties with reversed sequences.block to allow for easy deprotection in anticipation ofblocks used during heparin oligosaccharide assembly
Figure 5. Assembly of a Disaccharide with a Locked Iduronic Acid Acceptorrelate-specific heparin sequences and sulfation pat-
terns to protein binding and biological activity. The
purification of oligosaccharides after enzymatic diges-
tion of GAG chains has provided access to usable
quantities of oligomers up to hexasaccharides [72–74].
Chemical synthesis, although challenging in the con-
text of heparin oligosaccharides, has been used to pro-
cure defined sequences and analogs for biological
studies and to define SAR [10–12]. In this section, we
first briefly summarize the preparation of buildingfollowed by a review of the different general methods
used to prepare oligosaccharides.
Synthesis of Building Blocks for Heparin Synthesis
The preparation of sufficient quantities of fully dif-
ferentiated building blocks incorporating appropriate
protecting groups is particularly important for the syn-
thesis of complex oligosaccharides such as heparin.
The placement of specific temporary protecting groups
is required at the 4-hydroxyl group of each building
Chemistry & Biology
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737Figure 7. Different Pentasaccharides with
Xa Affinitychain elongation. Here, levulinoyl esters [75, 76], Fmoc
carbonates [77], silyl ethers [75, 78, 79], and PMB eth-
ers [80–82] have found use. The hydroxyl groups to be
O-sulfated at the end and those that should remain free
have to be protected differentially. Commonly, acetate
esters serve to mark the hydroxyl groups to be sulfated,
whereas benzyl ethers mask hydroxyl groups that will
not be modified. The amine group of D-glucosamine
requires the placement of different protecting groups.
Azides have been commonly used in this function [79,
82–84].
The choice of anomeric leaving groups presents an-
other important consideration in oligosaccharide as-
sembly. Increasingly efficient glycosylation reactions
have been developed, and glycosyl trichloroacetimi-
date and thioglycoside building blocks have replaced
methods requiring the use of heavy metal activators.
Commonly used, commercially available, and inexpen-
sive starting materials for the synthesis of differentially
protected glucosamine and glucuronic acid building
blocks are D-glucosamine and diacetone glucose.
Because L-iduronic acid is not accessible from natu-
ral sources, many strategies to obtain this monosac-
charide by manipulation of D-glucuronic acid deriva-
tives have been developed [85–95]. Recently, a host of
methods starting from D-glucuronolactone, D-diacetone
glucose, and D-glucuronic acid glycals as starting ma-
terials have been reported [8, 96–105]. Nevertheless,
the synthesis of iduronic acid building blocks remains
a major challenge en route to the desired heparin oligo-
saccharides.
Initially, total synthesis efforts targeted a single hepa-
rin oligosaccharide and yielded many valuable insights.
In recent years, modular approaches aiming at the syn-thesis of a broad range of heparin/heparan sulfate oli-
gosaccharide fragments have been developed.
Modular Synthesis of Heparin Oligosaccharides
The first modular assembly approach targeted the
common heparin disaccharide repeating unit 1 and its
6-O-unsulfated counterpart 2 (Figure 3A) [80]. Disac-
charide 1 was prepared in five steps from disaccharide
3 (29% overall yield) [85], whereas the assembly of 2
required eight steps (30% yield).
Another modular approach relied on the late stage
formation of uronic acids by selective oxidation of the
C-6 hydroxyl groups of glucose and idose residues.
Thus, problems such as epimerization of the C-5 posi-
tion of uronic acids and poor coupling efficiency of uro-
nic acid-based glycosylating agents were circumvented
[79]. It was calculated that 20 disaccharide building
blocks would be required to assemble all possible lin-
ear oligosaccharide chains.
Another synthesis to disaccharide subunits starts
from diacetone glucose 4 that was converted via
1,2:3,5-di-O-isopropylidene-β-L-idofuranose 5 to the
desired 1,6-anhydro-β-L-hexopyranose 6 (Figure 3B)
[107, 108]. Union of 6 and 7 upon TMSOTf activation
provided disaccharide 8. The α-isomer was isolated
and acetylated, and the 1,6-anhydro-β-L-idopyranosyl
ring was opened. Removal of the anomeric acetate af-
forded the desired lactol 9, ready for the next glycosy-
lation.
Six different monosaccharide building blocks that
can be combined to form the 20 disaccharides found
in heparan sulfate were prepared (Figure 4A) [106]. Four
different protecting groups (Lev, Fmoc, TBDPS, and All)
were employed in these syntheses. The Fmoc group
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738Figure 8. Preparation of Heparin Analogswas chosen to mark the C-4# hydroxyls for chain elon- d
ngation, whereas the anomeric center of the disaccha-
ride was protected in form of an allyl glycoside. Benzyl d
[ethers masked primary hydroxyls that were subse-
quently oxidized to carboxylic acids and secondary hy-
adroxyls that remain unsulfated. Levulinoyl esters were
utilized to protect the C-2# position to ensure stereosel- e
cective formation of 1,2-trans-glycosidic linkages. Fi-
nally, the C-6 position of glucosamine was protected as f
tTBDPS ether.
Two disaccharides (10 and 11) containing glucosam- S
Iines at the nonreducing end allowed for a systematic
approach to prepare inverse sequence (glucosamine- b
aiduronic acid) oligosaccharides in contrast to frag-
ments obtained by chemical or enzymatic processing o
sof polysaccharides (Figure 4B) [109].
The selective installation of the α-glucosamine glyco- s
hsidic linkage found in this disaccharide by coupling glu-
cosamine with an iduronic acid is the most challenging 1
etask in the synthesis of heparin oligosaccharides. A
new approach for stereochemical control of glycosyla- o
dtion reactions by controlling the conformation of the nu-
cleophile was developed [110]. Introduction of a cyclic (
nprotecting group (e.g., isopropylidene or cyclopentyli-ene) as conformational lock for the monosaccharide
ucleophile 12 ensured the exclusive formation of the
esired α-linked disaccharides (18 and 19) (Figure 5)
104].
Preparation of disaccharide building blocks by regio-
nd stereoselective glycosylation of an iduronic acid
ster diol with a 2-azido-2-deoxy-D-glucopyranosyl tri-
hloroacetimidate was also reported [111]. Four dif-
erent series of hexa- and octasaccharides were syn-
hesized with this disaccharide unit.
olid-Phase Synthesis of Heparin Oligosaccharides
deally, defined heparin sequences could be prepared
y automated solid-phase synthesis with methods
nalogous to those that already exist for the assembly
f oligonucleotides and peptides. Although automated
olid-phase synthesis of oligosaccharides is now pos-
ible [112], only a few polymer-supported syntheses of
eparin oligosaccharides have been disclosed [113–
15]. Soluble polyethylene glycol (PEG) polymers gave
ncouraging results for the synthesis of fully protected
ligosaccharides 22 that were obtained by coupling of
isaccharide 20 with polymer-bound iduronic acid 21
Figure 6A). Each elongation cycle incorporated levuli-
oate cleavage, coupling, and capping.
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with Pseudoalternating SequenceIn a second approach, disaccharide 23 was coupled
to polyethylene glycol monomethyl ether (MPEG) bound
disaccharide 24 to furnish MPEG bound tetrasaccha-
ride 25. Subsequent reaction of 27 with disaccharide
28 afforded MPEG bound hexasaccharide 29 that was
cleaved at the end from the solid support (Figure 6B).
This section summarized different approaches for the
modular synthesis of oligosaccharides. Future effort
will focus on the synthesis of larger quantities of hepa-
rin and heparan sulfate with an automated oligosaccha-
ride synthesizer to produce libraries of biologically sig-
nificant heparin and heparan oligosaccharides.
Synthesis of Heparin Oligosaccharides
with Anti-Factor Xa Activity
The anticoagulant activity of pentasaccharide DEFGH
(Figure 2B) prompted synthetic efforts aimed at the pro-
curement of this structure as well as a host of related
sequences (Figure 7). The first synthetic heparin oligo-
saccharide 30 with a high affinity for AT III was synthe-
sized in 1986 [116, 117].
α-methyl-glycoside 31, displaying the same biologi-
cal properties as 30, was prepared to simplify the
chemical synthesis [118, 119]. The synthesis of analogs
of 30 has been reviewed in detail [10]. Pentasaccha-
rides 32–36 were synthesized to establish a detailed
structure-activity relationship. Replacement of the re-
ducing end glucosamine by a glucose residue indicated
that O-sulfates are effective substitutes for N-sulfates
[119]. Introduction of an extra 3-O-sulfate group at the
reducing end of pentasaccharide 32 increased factor
Xa affinity [120]. Partial and complete O-methylation
(31–36) did not significantly alter AT III affinity [121, 122].
To assess the role of iduronic acid in the pentasac-
charide with Xa affinity we replaced this unit with a gly-
ceric acid oxymethylene linker to give 37 (Figure 8)[123]. These fragments are readily accessible and offer
the advantage that no α/β mixture is formed during gly-
cosylation. Coupling of 37 with glycosyl bromide 38,
followed by epimerization, gave 39. Union of 40 and
41 furnished trisaccharide 42. After deallylation, 43 was
coupled with 40 to afford pentasaccharide 44. The rep-
etition of deprotection and coupling steps afforded
heptasaccharide 45 and nonasaccharide 46.
Analogs 48–53 closely resemble heparin oligosac-
charides and their function but are simpler to synthe-
size. These so-called “nonglycosamino” glycans con-
tain only O-sulfate esters and O-alkyl ethers [75]. All
hydroxyl groups are permanently capped as methyl
ethers, thus eliminating the need to discriminate be-
tween nonsulfated and sulfated hydroxyl groups. Many
analogs with pseudo-alternating sequences have been
synthesized [124, 125].
Pentasaccharides 48–50 contain a common tetrasac-
charide composed of 2-O-sulfate and 3-O-methyl uro-
nic acid moieties, whereas pentasaccharides 51–53
contain an invariable tetrasaccharide composed of 2,3-
di-O-methyl uronic acid moieties (Figure 9). Pentasac-
charide 51, containing not less than seven methyl eth-
ers, displays the highest anti-Xa activity (1611 units/
mg) and is the most potent analog of 31 identified to
date.
Octasulfated pentasaccharide 54 containing an L-idu-
ronic acid unit in a fixed 1C4 conformation was synthe-
sized to determine whether the 1C4 or the 2S0 confor-
mation of L-iduronic acid is necessary for binding and
activation of AT III (Figure 10A) [126]. Pentasaccharide
54 exhibited very low anti-Xa activity, indicating that
either the 2S0 conformation of L-iduronic acid or a flexi-
ble L-iduronic acid residue, or the presence of both
conformers, is essential to bind and activate AT III.
Further studies involving different pentasaccharides
Chemistry & Biology
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rides
(A) Bridged heparin analog.
(B) Pentasaccharide with a C-interglyco-
sidic bond.
(C) Pentasaccharide 64, deoxygenated at
C-3 of unit G.
(D) Pentasaccharides containing iduronic
acid unit G locked in the 2S0, 1C4, and 4C1
conformation.
(E) Pentasaccharides with two carbon atoms
in the bridge.
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741Figure 11. Pentasaccharides Containing Charged Amino Groups at the Reducing Endindicated that a significant shift of the conformational
equilibrium from 1C4 toward the 2S0 conformation was
observed when the L-iduronic acid residue is adjacent
to a 3-O-sulfated glucosamine (unit F) [23]. The addi-
tional sulfate on unit F is the key structural element re-
sponsible for binding to AT III. Pentasaccharides with
an extra sulfate group introduced in unit H show higher
affinity for AT III, possibly because of the increased
presence of the 2S0 conformation [119].
Replacement of an O-glycoside by a C-glycosidicbond in anti-factor Xa pentasaccharides slightly de-
creased the affinities of 55 (880 units/mg versus 1180
units/mg) for AT III and anti-factor Xa (Figure 10B) [127,
128]. A C-3-deoxygenated L-iduronic acid residue was
incorporated as unit G to increase the 1C4-content of
iduronic acid (Figure 10C) [129].
Decrease of the nonbonding interactions between
C-3 and other axial substituents shifts the conforma-
tional equilibrium to render unit G predominantly in a
1C conformation (65%). The 2S conformer that pre-4 0
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742dominates in 58 (64%) is now considerably less abun- (
idant (24%). Because pentasaccharide 58 has a much
higher affinity for AT III than 57, the conformation of d
aunit G highly influences AT III affinity. Conformationally
locked pentasaccharides were prepared to further ad- a
tdress the influence of uronic acid conformation on AT
III binding. The L-iduronic units were locked in the 1C4 a
t(59) or 2S0(60) conformation by covalently bridging the
C-2/C-5 and C-3/C-5 ring atoms or in the 4C1(61) con- c
aformation by introducing a methoxymethyl substituent
at C-5 (Figure 10D) [101, 130]. u
RPentasaccharide 60 that contains an 2S0 iduronic
acid binds to AT III and can inhibit factor Xa (1073 units/ a
bmg). In contrast, the pentasaccharides 59 (43 units/mg)
and 61 (115 units/mg), having unit G locked in the 1C4 g
tor 4C1 conformation, respectively, exhibit little inhibitory
activity. The anti-Xa activity of compound 62 that con- e
tains a flexible G unit is similar to reference pentasac-
charide 51. a
wInsertion of one additional bridging carbon atom in
pentasaccharide 63 (Figure 10E) resulted in an iduronic a
macid that failed to adopt the ideal 2S0 conformation as
indicated by 1H-NMR-coupling constants [78]. The anti- t
bfactor Xa activity (1198 units/mg) of pentasaccharide
63 is similar to that of pentasaccharide 36 (1323 units/ c
img), and its biological activity is slightly better than that
of 60 (1073 units/mg) containing only one carbon atom a
tto bridge C-2 and C-5.
Three pentasaccharides, 64–66, containing the 2S0-
locked iduronic acid as well as various sulfate or methyl H
Agroups on the reducing end were synthesized to deter-
mine whether the absence of the noncritical sulfate A
agroups in unit H influences the biological activity [131].
The 3-O-sulfate in unit H increases the affinity for AT III L
fand shifts the equilibrium toward the 2S0 conformation.
The 6-O-sulfate group in H interacts with the 2-O-sul- r
sfate group on unit G resulting in enhanced biological
activity, whereas the removal of one of these sulfate p
tgroups results in lower activity.
The crystal structure of the AT III-pentasaccharide tTable 1. Different Oligosaccharides to Study Thrombin Binding
Nr TBD Spacer Length ABD Anti-Factor Xa Activity (units/mg) Antithrombin Activity (units/mg)
78 cellobiose (7-S) 53 51 740 10
79 maltotriose (10-S) 53 51 490 64
80 maltopentaose (16-S) 56 51 280 330
81 TBD=ABD (7-S) 53 51 770 14
82 TBD=ABD (9-S) 53 53 640 36
83 TBD=ABD (11-S) 53 50 280 160
84 maltopentaose (10-S) 18 51 540 1
85 maltopentaose (10-S) 32 51 700 15
86 maltopentaose (10-S) 46 51 420 20
87 maltopentaose (10-S) 59 51 630 120
88 maltotriose (16-S) 56 51 41 280
89 DS tetra (4-S) 53 51 2
90 DS tetra (5-S) 53 51 10
91 heparin tetra (6-S) 53 51 10
92 cellobiose (7-P) 53 51 500 22
93 cellobiose (7-IP) 53 51 690 5
94 maltotriose (10-P) 51 1000 167
36 T18-Oligonucleotide 51 173 5
51 — 1611 —
Heparin oligosaccharide ±50 160 16067) complex illustrates that all carboxylate groups are
nteracting with the positively charged Lys and Arg resi-
ues of AT III [52]. The carboxylate groups of Glu113
nd Asp117 are separated from the α-O-methyl group
nd the anomeric center. Therefore, the exchange of
he α-O-methyl group in 51 by an α-C-glycosidic ethyl-
mine tether should result in an additional binding in-
eraction with Glu113 and Asp117 in AT III. Pentasac-
harides 68–77 having one or two positively charged
mino groups at the reducing end were prepared (Fig-
re 11) [132]. The R1 sulfate of 68 as well as the R1 and
2 sulfates in 73 were replaced by methyl groups in 69
nd 74 to minimize unwanted intramolecular salt bridges
etween the terminal amino group and the sulfate
roups. Pentasaccharides 70 and 75 contained addi-
ional positively charged amino substituents on the
thylamino tether.
All pentasaccharides were less active than 51. The
mino groups in 71 and 76 are not interacting favorably
ith the negatively charged target amino acids Glu113
nd Asp117. Based on the lower activity of 74 (77 units/
g) compared to 69 (21 units/mg), it can be concluded
hat the 6-O-sulfate may form an intramolecular salt
ridge with the amine. Incorporation of two positively
harged groups (70 and 75) results in decreased activ-
ty (18 units/mg) and further suggests that the amino
cid residues are not available for additional binding in-
eractions.
eparin Oligosaccharides with Full
nticoagulant Properties
ll pentasaccharides described above exhibit strong
nti-factor Xa activity but fail to inhibit thrombin.
onger heparin chains (14–20 saccharides) are required
or antithrombin activity. Long, sulfated oligosaccha-
ides can be obtained by connecting two sequences
uch as ABD and TBD through a spacer. Several as-
ects need to be considered in defining the nature of
he spacer: (1) the type of the spacer (charged or neu-
ral; linear, flexible, or rigid), (2) the direction of chain
Review
743elongation (from the reducing end or nonreducing end),
and (3) the structural requirements of the thrombin
binding domain of heparin.
With these considerations in mind, a model of a hep-
arin/AT III/thrombin complex containing different glyco-
conjugates in the AT III binding domain ABD, a linear
spacer (50 atoms in length corresponding to an oligo-Figure 12. Heparin Oligosaccharides with Full Anticoagulant Activity
(A) Glycoconjugate derived through dimerization.
(B) Alternative TBDs for thrombin inhibition.saccharide of 12–18 units), and a persulfated maltotrio-
side representing the thrombin binding domain TBD
was prepared [133]. The model suggests that TBD
should be attached via the linker at the nonreducing
end of ABD. Different, short, persulfated oligosaccha-
rides 78–91 were synthesized and attached to ABD (51)
to study the binding of TBD to thrombin. Compounds
Chemistry & Biology
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pand antithrombin activity and indicate that an increase
in charge of the TBD unit results in higher antithrombin a
sactivity (Table 1).
The synthesis of symmetric conjugates that are able
Ato bind AT III on one end and thrombin on the other end
was also of interest. Therefore, pentasaccharides 50, C
g51, and 53 containing seven, nine, and eleven sulfates
were dimerized to produce glycoconjugates 81–83 (Fig- g
ture 12A).
Based on these findings, it was concluded that t
hantithrombin activity increases with the number of sul-
fate groups. The number of sulfates in the thrombin
wbinding domain appeared to be more important than
the number of carbohydrates. The influence of the w
wlength of the spacer was investigated with conjugates
84–87. With an 18 atom spacer, only anti-factor Xa ac- g
ptivity was observed, whereas the incorporation of a 32
atom spacer induced some antithrombin activity. An in- e
icrease in spacer length to 46 or 59 atoms resulted in a
sharp increase in antithrombin activity. Conjugate 88 a
swas synthesized to establish if reduction of the AT III
affinity of the pentasaccharide in a conjugate affects c
both the anti-factor Xa and antithrombin activity. Conju-
gate 88 is similar to 80 but contains a pentasaccharide a
9with a 50-fold-lower activity for AT III. Surprisingly, the
antithrombin activity of 88 is almost identical to that of s
n80 but exhibits a 7-fold-lower anti-factor Xa activity. An
explanation for this phenomenon could be that in case m
lof conjugate 88, the assembly of the ternary complex
occurs through the expected binary AT III-88 complex. c
AThis leads to an anti-factor Xa and antithrombin activity
and a binary thrombin-88 complex that leads only to an t
AT III-mediated antithrombin activity. The formation of
the latter binary complex occurs more easily relative aFigure 13. Example for a Noncarbohydrate
TBDo the thrombin-heparin binary complex because the
entasaccharide domain of conjugate 88 has a lower
ctivity for AT III, whereas its thrombin binding domain
hould interact more strongly with thrombin.
Heparin-like conjugates 89–91 that contain identical
BD but different TBD domains were prepared [134].
onjugate 89 contains a TBD domain with four sulfate
roups and exhibited low antithrombin activity. Conju-
ates 90 and 91 showed an antithrombin activity similar
o 78. The charge density of the TBD moiety determines
he antithrombin inhibitory activity, whereas the carbo-
ydrate structure of TBD has no effect.
Perphosporylated cellobiosyl saccharides 92 and 93
ith seven and 14 negative charges, respectively, as
ell as maltotrioside 94 carrying 20 negative charges
ere synthesized to probe the effect of the charged
roup on high affinity ABD domains (Figure 12B). Incor-
oration of lipophilic groups into the TBD domain was
xpected to enhance the interaction with thrombin. The
ntroduction of a phosphate ester in TBD increased its
ffinity for thrombin, whereas the replacement of one
ulfate group by a phosphate ester in the ABD de-
reased its affinity of ABD for AT III.
Based on the observation that oligonucleotides can
ssociate with the heparin binding site [135], conjugate
5 (Figure 12B) was prepared in which part of the
pacer and the TBD domain were replaced by an oligo-
ucleotide. The low anti-factor Xa activity (173 units/
g) and antithrombin activity (5 units/mg) of 95 il-
ustrated the existence of a weak interaction of oligonu-
leotides with the TBD domain. The interaction of the
TB domain with AT III requires more than just the in-
eraction of the TBD domain with thrombin.
N-(2-Naphthalenesulfonyl)-glycyl-(D)-4-aminophenyl-
lanyl-piperidine (NAPAP) derivate 96 served as an-
Review
745Figure 14. Heparin Oligosaccharides with Different Spacers
(A) Carbohydrates with full anticoagulant properties for heparin.
(B) Oligosaccharide with a permethylated polymaltose spacer.
(C) Retrosynthetic way for the synthesis of glycoconjugates with a rigid spacer.
(D) Heptadecasaccharide, not neutralized by PF4.
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other noncarbohydrate TBD (Figure 13) [136]. NAPAP i
97 itself binds directly to the active site of thrombin s
(EC50 = 0.75 M). The NAPAP-conjugate 96 was de- a




Xa Activity Activity IC50 nNr Size (units/mg) (ng/mL)
101 10-mer 325 > 10,000 b
102 12-mer 405 > 10,000
a103 14-mer 360 > 10,000
t104 16-mer 310 130
a105 18-mer 360 23
106 20-mer 290 6.7 b
Heparin - 170 3 t
108 15-mer 370 41 s
109 17-mer 270 5.3 h110 19-mer 290 1.7
o111 17-mer 270 9.3
I112 16-mer 350 490
a113 18-mer 260 360
114 20-mer 210 88 i
oaccharide, results in a much-simplified synthesis of
Figure 15. Different Heparin Mimetics
(A) Heparin mimetic with low sulfated sequence.
(B) Heparin mimetics to proof the location of the TBD domain.ty and to inhibit thrombin. Indeed, conjugate 96 exhib-
ted antithrombin activity (IC50 = 0.35 M) and anti-
actor Xa activity (885 units/mg) and confirmed that the
APAP conjugate is a better inhibitor than the combi-
ation of the free pentasaccharide and NAPAP.
All approaches discussed thus far incorporated a flexi-
le spacer. Another class of oligosaccharides containing
rigid spacer and a decreased charge density was syn-
hesized. ABD domains with at least six negative charges
lso served as a TBD because the interaction of throm-
in with heparin results from an electrostatic attraction
hat depends on the density of negative charges. It
hould be noted that AT III-ABD binding affinity is much
igher than thrombin-TBD binding affinity. A sequence
f repeating ABD’s would increase the affinity for AT
II, but prevent thrombin binding. Oligosaccharides with
nti-factor Xa and anti-thrombin affinity require an affin-
ty of AT III-ABD and thrombin-TBD in the same order
f magnitude. Based on the high AT III affinity of penta-
accharide 49, hexasaccharides consisting of a repeat-
ng disaccharide unit should have a reduced but still
ignificant affinity for AT III. The highly symmetrical
ntithrombin binding domain, obtained from a single di-
Review
747Figure 16. Oligosaccharides Involved in FGF Interactionglycoconjugates for drug development. The first carbo-
hydrates exhibiting full heparin anticoagulant proper-
ties were synthesized in 1998 [137, 138].
Three hexasaccharides that contain one additional
trisulfated glucose unit at the nonreducing end (98), a
D-glucuronic acid (99), or an L-iduronic acid as the only
uronic acid in the compound (100) were synthesized
(Figure 14A). The introduction of the additional trisul-
fated glucose in 98 results in binding to AT III. The bind-
ing affinity of 99 that contains only D-glucuronic acids
decreased dramatically. Oligomer 100, which contains
only L-iduronic acids, displayed ideal binding proper-
ties with an affinity for AT III (Kd = 0.35 M) similar to
the heparin-thrombin binding (Kd = 1 M). Anti-factor
Xa activity of 100 was reported at 325 units/mg.
Based on these findings, larger heparin fragments re-
lated to 100 were synthesized [139]. All compounds





133 Glc-GlcNS-Glc-GlcNS-Idooligosaccharides (hexa-, octa-, deca-, dodeca-, and te-
tradecamer) do not inhibit thrombin, whereas for larger
oligomers (hexadeca- [104], octadeca- [105], and eico-
sasaccharide [106]) activity increases with size. The ei-
cosamer is half as potent as standard heparin (Table 2).
Exchange of the polyethylene glycol spacer to a rigid
permethylated polymaltose spacer (107) increased the
antithrombin activity 10-fold, whereas anti-factor Xa
activity remained similar to 80 (Figure 14B). Because of
the lower charge density and the rigidity of the spacer,
neutralization of 107 by PF4 was reduced by a factor
of 20 when compared to standard heparin [140].
Glycoconjugates 108–110 possessing a specific ABD
domain and a TBD domain that is not recognized by AT
III were synthesized to create oligomers with a charge
density similar to that of heparin (Figure 14C) [141].
Preparation of these structures relied on elongation of
the ABD domain at the nonreducing end by the addition
of 3-O-methyl-2,6-di-O-sulfo-D-glucose oligomers with
alternating α, and β (1/4) linkages.
Anti-factor Xa activity and affinity for AT III were sim-
ilar for all compounds, whereby thrombin inhibition in-
creased with growing chain length. Nonadecamer 110
was as potent as the most active fraction isolated from
standard heparin. Heptadecasaccharide 111, which
contained even less charge density, exhibited the same
anticoagulant properties but could not be neutralized
Chemistry & Biology
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i(Figure 14D) (Table 2) [142].
A new family of heparin mimetics (112–114) combined A
aa pentasaccharide ABD domain with a TBD domain
composed of a low sulfated sequence of repeating 2,3- G
hdi-O-methyl-6-O-sodium sulfonato-α-D-glucosyl units
(Figure 15A) [143]. Only small differences in the AT III r
paffinity and in the inhibition of Xa were observed. These
conjugates are less potent than heparin, but none are
tneutralized by PF4, indicating that this group of mole-
cules may constitute alternatives to standard heparin 1
r(Table 2).
Until 2001, there was no experimental proof that the s
hthrombin binding domain in heparin is located at the
nonreducing end of the antithrombin binding domain F
and that the factor Xa inhibition is not affected by elon-
gation of the antithrombin binding pentasaccharide se- p
aquence. Different heparin mimetics were used to inves-
tigate this hypothesis (Figure 15B) [76]. The N-sulfated i
tglucosamine units of heparin were replaced by O-sul-
fated glucose, and O-methyl groups were incorporated m
fin place of hydroxyl groups to simplify the synthesis. In
the TBD domain, 2,6-di-O-sulfonato-β-D-glucose sub- F
rstituted 2-O-sulfonato-α-L-iduronic acid to maintain the
number of charges per saccharide unit as in heparin. t
fAll analogs (115–118) exhibited the same activity for
anti-factor Xa and affinity for AT III. Again, inhibition of T
nthrombin was increasing with chain length. Oligosac-
charide 118 does not inhibit thrombin in the presence c
nof AT III. These results demonstrate that the TBD must
be located at the nonreducing end of ABD to inhibit
sthrombin.ynthesis of Heparin Oligosaccharides Involved
n FGF Interaction
fter the minimum heparin binding sequence for FGF1
nd FGF2 had been determined (HexA-GlcNS-HexA-
lcNS-IdoA-2OS), different syntheses to access these
eparin fragments were developed. The oligosaccha-
ides differ in configuration of the HexA units, sulfation
attern, and length.
Tri (119 and 120)- and tetrasaccharide (121) deriva-
ives were synthesized with a modular strategy (Figure
6) [144]. This modular strategy also yielded disaccha-
ides 122–127 and trisaccharides 128 and 129 [145]. Di-
accharide 124 and 125 bind to FGF2 less tightly than
eparin. The two trisaccharides 128 and 129 bind to
GF2 and show higher affinity for FGF1.
Four different pentasaccharides 130–133 were pre-
ared to elucidate the exact nature of the hexuronic
cid unit (Table 3) [84, 146]. All pentasaccharides inhib-
ted FGF2 binding to heparin or heparan sulfate and
he proliferation of FGF-induced human aortic smooth-
uscle cells (HASMC). Pentasaccharide 130 is most ef-
ective, whereas 131–133 showed only weak potency.
rom these observations, it was concluded that idu-
onic acid is mainly responsible for the interaction be-
ween heparin and FGF2. The conformation of the dif-
erent iduronic acid residues was analyzed by NMR.
he iduronic acid at the nonreducing end is predomi-
antly present in the 4C1 form. The iduronic acid in the
enter prefers the 1C4 form, and the reducing end iduro-
ic acid adopts the 2S0 conformation.
Tetrasaccharide and hexasaccharide methyl glyco-
ide 134 and 135 were prepared from three different
Review
749Figure 18. Oligosaccharides with Different Sulfation Patterndisaccharides: seeding disaccharide 138, elongation
disaccharide 137, and capping disaccharide 136 (Fig-
ure 17) [81]. Within each disaccharide, iduronic acid
was placed at the nonreducing end and glucosamine
at the reducing end. Hexasaccharide 135 antagonized
iodinated heparin-FGF2 binding and inhibited FGF2-
induced proliferation of human aortic smooth-muscle
cells (HASMC), whereas tetrasaccharide 134 showed
only weak efficacy.
Three tetrasaccharides 139–141 containing the se-
quence GlcN-IdoA and different sulfation patterns at
C-6 of the glucosamines were prepared (Figure 18)
[147]. The synthesis relied on the coupling of two versa-
tile disaccharide building blocks with orthogonal pro-
tecting groups [109]. The same strategy followed by a
convergent n + 2 block approach allowed the prepara-
tion of longer oligosaccharides, which are not available
by enzymatic or chemical degradation of heparin with
a glucosamine unit at the nonreducing end [148–150].
Hexa- 142 and octasaccharide 143 contain the struc-
tural motif of the major region of heparin and were
tested for activation of FGF1. Octasaccharide 143 acti-
vates the mytogenic signal like heparin, whereas hexa-saccharide 142 was less efficient. From sedimentation
experiments, it has been concluded that the active form
of FGF1 is a monomer, assuming that the dimerization
of FGF1 is not necessary for FGF1-induced signaling.
Hexasaccharide 142 prefers a helical conformation,
and the iduronic acid units exist in a fast equilibrium
between the 2S0 and the 1C4 form with a slight prefer-
ence for the latter. Comparison of the conformation of
142 with that of pentasaccharides 130–133 reveals that
the sequence of the oligosaccharides (IdoA-GlcN ver-
sus GlcN-IdoA) can affect the conformation of the idur-
onic acid units.
Because the interaction of heparin with several pro-
teins, including FGFs and their receptors, is mediated
by Ca2+ [151–155], further investigations on 142 have
been performed. Electrostatic interactions of heparin
with ions occur via charged saccharide groups. Calcium2+-
heparin interactions in which the cation binds preferen-
tially to the carboxylate groups of the iduronic acid
units have been observed. Modification of the carbox-
ylate groups by conversion into methyl esters or by pro-
tonation resulted in the loss of binding capability. The
lack of the sulfamido group of the glucosamine units
Chemistry & Biology
750Figure 19. Heparin Oligosaccharides Recognized by Herpes Simplex Virus
(A) Target structure binding to HSV-1 with unknown stereochemistry at the indicated center.
(B) Synthesis of hexasaccharide 153.results in the loss of Ca2+ binding to heparin. Combina- H
ation of size and charge is responsible for site-specific
Ca2+ binding, whereas other ions (e.g., Na+ and Mg2+) r
bind more specifically.
Binding of Ca2+ to 142 was found to be specific [156, h
c157]. The ion influences the backbone flexibility and ri-
gidifies the glycosidic linkage, and the conformational t
oequilibrium of the iduronic acid unit may be shifted to
the 1C4 conformation. NMR-spectroscopical studies of C
disaccharide unit 144 confirmed that the 1C4 conforma-
tion showed also here the highest affinity for Ca2+. Fur- f
athermore, the ion coordinates the carboxylate and 2-O-
sulfate groups of the iduronic acid units as well as the T
tN-sulfate moiety of glucosamine with the glycosidic
and iduronate ring oxygen atoms. Calcium-heparin in- q
steraction studies were extended to hexasaccharides
147 and 148 [158]. NMR studies in concert with molec- c
sular modeling revealed that the 6-O-sulfate group of
glucosamine is necessary for the interaction of heparin u
twith Ca2+, whereas the sulfate group at C-2 of iduronic
acid is not required. Hexasaccharide 145 and octa- s
ssaccharide 146 were prepared with the convergent n +
2 block approach to test whether the active form of t
oFGF is a monomer [149]. Exhibiting charged groups
only on one side of the helical structure, a monomeric a
complex with FGF1, should be formed exclusively. Con-
formational analyses showed that the absence of the S
b2-O-sulfate groups in C and G, the 6-O-sulfate group in
B and F, and the N-sulfate group in D and H do not H
change the conformation of the iduronic acid rings.exasaccharide 145 was found to be biologically active
nd demonstrated that a 1:1 complex between a hepa-
in fragment and FGF1 can induce mitogenesis.
The closely related hexasaccharides 147 and 148
ave the same sequence as 142 and 145, but their
harge distribution has been designed to gain struc-
ural and biological information to study the importance
f sulfate groups glucosamine C-6 and iduronic acid
-2 [150].
The oligosaccharides contain the basic structural
eatures of heparin, but different charge distribution
nd orientation results in a different biological behavior.
he two oligosaccharides 142 and 143 contain the
risaccharide motif (IdoA-2OS-GlcN-6OS-IdoA-2OS) re-
uired for high affinity binding to FGF1, whereas oligo-
accharides 145–148 were missing this motif. Oligosac-
harides lacking this internal trisaccharide motif can
timulate FGF1 more efficiently than those with the reg-
lar heparin structure [159]. Hexasaccharide 145 con-
aining sulfate groups only on one side of the helical
tructure can activate FGF1 as effectively as octa-
accharide 143. These results underscore the impor-
ance of charge distribution in the activation process
f FGF1 and suggest that the FGF dimerization is not
bsolutely required for biological activity.
ynthesis of Heparin Oligosaccharides Recognized
y Herpes Simplex Virus
eparan sulfate serves as adhesion receptor for bacte-ria, parasites, and viruses. Its negative charges can be
Review
751Figure 20. Compounds 155–165 to Investigate Platelet Binding Activitiesrecognized by viral proteins [160]. Herpes simplex
viruses (HSVs) are members of the neurotropic sub-
group of the herpes virus family. Infection with herpes
simplex virus 1 (HSV-1) and herpes simplex virus 2
(HSV-2) are most common in humans. HSV-1 binds to
cells by interaction of envelope glycoproteins gB and
gC with cell-surface heparan sulfate. A third viral glyco-
protein, gD, is interacting with one of multiple specific
receptors, which results in a viral entry of the virion en-
velope with a cell membrane. This fusion requires the
concerted action of the three glycoproteins and is trig-
gered by the binding of gD to its cognate receptors. Aheparan sulfate octasaccharide (149) that binds to
HSV-1 gD was identified (Figure 19A) [161–163].
Based on this information, a fully protected N-dif-
ferentiated heparin oligosaccharide was prepared in ef-
forts to establish a structure-activity relationship [164].
Because of the limitations of the analytical methods,
the nature of one of the uronic acid residues was not
known. Therefore, initially, an iduronic acid residue was
selected in this position. The protecting-group strategy
was adapted from previous heparin syntheses: O-sulfo-
nates were masked as O-acetates, hydroxyl groups as
O-benzyl ethers, carboxylic acids as methyl esters, and
Chemistry & Biology
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protected as benzylcarbamate and the N-diacetate as
N-acetate.
Two disaccharides, 150 and 151, and tetrasaccharide
152 were readily prepared. Coupling of 151 and 152 af-
forded hexasaccharide 153 as an α/β mixture (6:1) and
the rearranged tetrasaccharide 154 (Figure 19B). The
selectivity is decreased by the 2-N-CBz glucosamine
residue that could force the iduronic acid unit out of the
favorable 1C4 conformation. This finding underscores
that the selectivity of glycosylation reactions is greatly
influenced by the formation of the nucleophile. This fact
has to be taken into consideration for further syntheses
of large heparin-like glycosaminoglycans.
Synthesis of Heparin Oligosaccharides Interacting
with Platelets
Heparin binds to platelets and can cause activation and
aggregation. The platelet binding site for heparin has
to be determined to understand how heparin is altering
platelet function. Given the heterogeneous nature of
heparin, this is a challenging task. A disaccharide unit
(GlcNS[6-OS]-IdoA[2-OS]) in heparin was found to be
the key for the binding interaction [165]. The disaccha-
ride cannot be obtained by enzymatic or chemical deg-
radation. Therefore, a series of oligomers 155–160 con-
taining this disaccharide were prepared, and their platelet
binding activities determined (Figure 20) [166, 167].
Compound 156 and 160, which contain three units
of GlcNS(6-OS)-IdoA(2-OS), bound stronger than their
counterparts 155, 158, and 159, which contain only two
key disaccharides. These findings underscore the role
of the GlcNS(6-OS)-IdoA(2-OS) clustering effect for
binding. The binding potency is not influenced by the
distance between the GlcNS(6-OS)-IdoA(2-OS) units.
Head-to-tail dimer 157 has a higher binding activity
than the tail-to-tail dimer 155. The arrangement of the
two units of GlcNS(6-OS)-IdoA(2-OS) has an influence
on the activity.
Pentasaccharide 31, which does not contain the key
disaccharide GlcNS(6-OS)-IdoA(2-OS), binds to plate-
lets. Fragments of 31 were synthesized to determine
which part of 31 is responsible for the platelet binding.
The tetrasaccharide that contains the nonreducing
fragment DEF of 31 does not bind platelets. More de-
tailed studies were focused on the reducing end FGH
trisaccharide 161 and on its partially desulfated deriva-
tives 162 and 163 as well as on disaccharide deri-
vatives 164 and 165 (Figure 20). Only trisaccharide
161 bound comparably to 156 and 160. Based on these
results, it has been suggested that the sequence
GlcNS(3-OS)(6-OS)-IdoA(2-OS)-GlcNS(6-OS) is a high-
affinity binding site for platelets.
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